Aeovian � AE116

Aeovian is a San Francisco Bay Area-based research stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases. They are developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress. Their lead compounds are novel and highly selective therapeutics that potently inhibit the mTORC1 pathway. Genetic mutations and aging result in abnormal activation of mTORC1; normalization of its aberrant activity is, therefore, necessary to combat rare and age-related disease pathologies and enable therapeutic treatment. Addressing the mTORC1 pathway has been challenging to-date however, because chronic treatment with conventional, non-selective mTOR inhibitors, such as rapamycin and Everolimus, leads to off-target inhibition of mTORC2 which results in dose-limiting deleterious effects on metabolic health and immune function. The associated toxicity leads to severe clinical adverse events that significantly reduce treatment safety, decrease compliance, and compromise therapeutic efficacy. CEO Dr. Allison J. Hulme & CSO Dr. John F. Kincaid.